Madam Chairman, first I have to say that we wouldn't be here, not only for his substantive contributions to this legislation, but because of his suggestions about the approach we should take, whether it was in full committee or as we move…
Madam Chairman, first I have to say that we wouldn't be here, not only for his substantive contributions to this legislation, but because of his suggestions about the approach we should take, whether it was in full committee or as we move towards the floor in terms of working out problems that existed, and that's Chairman Conyers. He played a critical role in getting us to this point.
Lamar Smith, Howard Coble, Rick Boucher, who I started this with, Darrell Issa, Zoe Lofgren, Adam Schiff, Bob Goodlatte, a number of people played key roles in all this. I don't have too much time. The staff, on an issue like this, was indispensable; they made incredible contributions. This is really complicated stuff. Perry Apelbaum who demonstrated great leadership and guidance on many issues, George Elliott, a detailee from the Patent Office who is a great resource, Karl Manheim, who decided to spend his sabbatical helping on patent reform, Eric Gorduna who spent his summer working on the committee report, countless other staff, and of course my Chief Counsel Shanna Winters.
But the question is why, why are we doing this? And here are the things we are told by groups like the National Academy of Sciences and so many other organizations that are tremendously respected for their understanding of science and of our economy:
One, there are serious problems in the patent system;
Two, many poor-quality patents have been issued, which cheapen the value of patents generally;
Three, there have been a variety of abuses in patent litigation rules that have taken valuable resources away from research and innovation;
Four, U.S.-based businesses are disadvantaged because our patent laws aren't harmonized with the rest of the world.
Many organizations, many groups have argued for these reforms.
A quick statement about support. Every major consumer group in this country has endorsed this legislation. There is tremendous support in the financial services sector, in the high technology sector. The universities have now, University of California, which is one of the critical magnets of research and development, have supported passage of this legislation through the House. The American Association of Universities has supported moving the bill forward.
And one last comment. There is one very controversial issue, aside from the ones addressed by the amendments that we have seen that are not fully dealt with, and that particularly relates to the issue of damages and the apportionment of damages. It is our commitment, my commitment, the chairman's commitment, Mr. Smith's commitment, Mr. Coble's commitment, to work with people who are concerned about that language to reach an appropriate middle ground that reforms the way damages are calculated between now and the conference committee and when this comes back to deal with that controversy.
I urge strong support for this bill so we can make this historic effort, first in 60 years, move forward to ultimate enactment.
I include short list of the range of groups that support this bill.
The Business Software Association, The Financial Services
Roundtable, Small Business & Entrepreneurship Council,
TechNet, Consumer Federation of America, Consumer Union,
Electronic Frontier Foundation, Knowledge Ecology
International, Public Knowledge, United States Public
Interest Research Group, American Corn Growers Association,
American Agricultural Movement, Federation of Southern
Cooperatives, National Family Farm Coalition, National
Farmers Organization, Rural Coalition, Securities Industry
and Financial Markets Association, Computer and
Communications Industry Association, Computing Technology
Industry Association, Illinois IT Association, Information
Technology Association of America, Information Technology
Industry Council, Software & Information Industry
Association, St. Jude Medical, Massachusetts Technology
Leadership Council, Inc., Hampton Roads Technology Council,
Northern Virginia Technology Council.
I thank the gentleman for yielding.
Madam Chairman, just because the gentleman says it is so, doesn't mean it is so. I have letters from the AFL-CIO, the university community, and the major centers of innovation and research in this country that directly contradict his assertion that they are opposed to the passage of this bill. The Members of this body should understand that.
Mr. Chairman, will the gentleman yield?
Under the entire market value rule, which is in this bill, the Wright brothers, every value of what was created was those surface controls.
I thank the gentleman for yielding, and I would like to yield to the gentleman from Oregon for purposes of a colloquy.
That is a provision that I have supported, it is legislation I have introduced, it embodies and enacts a philosophy I completely agree with. All PTO fees should be kept within the PTO office to reduce backlogs, to hire qualified people, and to come to better operations of that critical office.
The chairman of the committee obviously will be a key
member of the conference committee and indicates that he feels the same way.
Reclaiming my time, I just want to make a couple of points.
First, I have never said, quote, Labor supports this bill. What I said was Labor thinks a number of improvements have been made, particularly in this manager's amendment. There are other issues that concern them, that they believe we are moving in the right direction, and that they have no opposition to the passage of this bill, understanding they have other concerns that want to be addressed.
The same applies for a number of pharmaceutical companies. The major institution, and they are not small guys, Mr. Rohrabacher. Opposition to this, concerns about this bill, come from large and important--
Mr. Chairman, I demand a recorded vote.
I thank the gentleman, I also agree with the amendment. I would like to use the time, if you would allow me to finish the sentence, which is with respect to these important companies, that, in the biotechnology and pharmaceutical field, I just want to repeat, a number of things they want, first-inventor-to-file, not first-to-file, first-inventor-to-file, repeal of the best-mode defense, reform of the inequitable-conduct defense, are in this bill, and we intend to work with them on the damages issue between now and a final conference report to try to come to a better understanding on that very important, but very complicated, field.
I thank the gentlelady, and I support her amendment.
Just to review the bidding, my friend from California (Mr. Rohrabacher) over and over again talks about the flaws in this bill. Other than four Gohmert amendments on the issue of venue and one amendment from the gentleman from Iowa that was an earmark amendment, no other amendments were kept from consideration here. For all the arguments about flaws, where were the amendments to correct the flaws that they talk about? For all the notions of, we're not against reform, but this one isn't perfect, and this one isn't right, and this has some flaws, and it hasn't resolved every issue to everyone's satisfaction, nothing will, where is their alternative bill?
I'm telling you, this is an issue of whether we're going to address a system that the National Academy of Sciences and so many other objective agencies have said is getting near broken or doing nothing, and I suggest doing nothing is not a good answer for a Congress that wants to keep the American economy strong.